Core Viewpoint - An investor is pushing for a complete board overhaul at Avadel Pharmaceuticals due to perceived mismanagement, particularly regarding the launch of its primary narcolepsy treatment, which has led to significant revenue losses [1][2]. Group 1: Company Management and Governance - ASL Strategic Value Fund intends to call for a shareholder vote to remove the entire board of directors at Avadel Pharmaceuticals, indicating rising dissatisfaction with management [1]. - The fund plans to release an open letter detailing claims that Avadel has mismanaged the launch of its main treatment, resulting in missed revenue opportunities amounting to hundreds of millions of dollars [2]. Group 2: Competitive Landscape - Avadel Pharmaceuticals has been engaged in ongoing litigation with its largest competitor in the narcolepsy treatment market, highlighting the competitive pressures the company faces [3].